Clinical study on Astragalus and Angelica with oseltamivir phosphate granules in treating influenza in diabetics
10.3760/cma.j.cn112866-20200514-00164
- VernacularTitle:"黄芪-当归"联合磷酸奥司他韦治疗糖尿病患者流感病毒感染初步临床研究
- Author:
Yue MING
1
;
Yexing WANG
;
Jiayi QIAN
;
Kuo QIAN
;
Jian GONG
Author Information
1. 齐齐哈尔医学院 161006
- Keywords:
Oseltamivir;
Astragalus;
Angelica;
Influenza
- From:
Chinese Journal of Experimental and Clinical Virology
2020;34(6):644-648
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of oseltamivir phosphate combined with Astragalus and Angelica on treatment of diabetics with influenza virus infection and immunologic function, and observe the influence on the serum inflammatory factors.Methods:A total of 84 diabetics with influenza virus infection who were treated in the Third Affiliated Hospital Qiqihar Medical College March 2016 to December 2019 were recruited as the study objects and randomly divided into the combination group and the control group, with 42 cases in each group. The control group was treated with oseltamivir phosphate capsules on basis of the conventional therapy, while the combination group was given combined Astragalus and Angelica on basis of the treatment of the control group. The effective rate of treatment was compared between the two groups of patients, the time of disappearance of clinical symptoms and adverse reactions during treatment were recorded. The immunologic function and levels of serum inflammatory factors C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were compared between the two groups of patients before and after the treatment.Results:The time of clinical symptoms of influenza was significantly shorter than those of the control group ( P<0.05); the immune function of the patients in the combination group was significantly enhanced compared with that in the control group ( P<0.05); The total effective rate of treatment of the combination group was, significantly higher than of the control group ( P<0.05); The levels of serum inflammatory factors CRP, IL-6 and TNF-α of the two groups of patients declined after the treatment, and the above measurements were improved better in the combination group than in the control group ( P<0.05); the patients of the combination group did not have any adverse reactions that were related to the combined use of the medicines. Conclusions:Oseltamivir phosphate combined with Astragalus and Angelica effectively relieved the clinical symptoms of the patients with influenza virus infection, alleviated the inflammatory reactions and accelerated the recovery of the patients.
